Once-daily treatment for canine atopic dermatitis
Delivers 6-in-1 parasite protection for cats
Valuable discounts, expert information, and tips
See how injectable medications offer value beyond the prescription
The first and only FDA-Approved veterinary antiemetic
The first long-lasting monoclonal antibody therapy for canine atopic dermatitis
Vaccination for the prevention of respiratory disease caused by BRSV
The beef industry’s No. 1 branded preconditioning program
Exclusive pricing program for Cattle producers
Outstanding protection against costly respiratory and reproductive diseases
Treatment and control of gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites
Innovative food safety products that help deliver a farm-to-fork solution for beef
The most comprehensive guarantee available
First and only FDA-approved antibiotic for horses that offers a full course of therapy in just two doses
Annual vaccination with CORE EQ INNOVATOR helps provide the protection your horse needs
Treats and controls encysted small strongyles, bots and roundworms. QUEST PLUS contains an additional active ingredient for efficacy against tapeworms
Patented and scientific method of determining fair service pricing to improve your clinic's profitability
Connect directly to valuable dairy management resources and experts
The most "veterinarian recommended" and "producer used" prostaglandin in the market
Delivers the peace of mind and profitability that come with no milk discard
Effective and convenient treatment for acute metritis in cattle
Working together to improve reproduction
One injection treats and controls swine respiratory disease for 7 days
Protect sows and gilts from costly breeding herd diseases — parvovirus, leptospirosis and erysipelas
The industry standard for in ovo technology.
Full automation solutions for hatchery automation
Prevention and control of necrotic enteritis, increased rate of weight gain and improved feed efficiency in poultry
for the prevention of coccidiosis in poultry
modified-live vaccine that helps poultry companies reduce their overall Salmonella load
Blood glucose monitoring system
Smart new diagnostics platform that can reinvent your in-house diagnostic routines
Detect Johne’s Disease with confidence in cattle and goat herds
Simple and effective detection of a deadly Feline Virus
Accurate, affordable and easy to use
Order Beef Genetics products online
Order Dairy Genetics products online
Delivers reliable predictions of genetic merit based on test results of core traits
Represents the latest advancement in Angus genotyping technology.
Register today to learn more
Become a more effective leader
Looking for a tailored experience?
Earn continuing education credits and stay current on industry developments with Zoetis’ convenient, on-demand learning solutions.
Veterinarians, Veterinarian Techs, Business Owners, and Farm Hands
Launch your veterinary career
Veterinarian Students and Recent Graduates
Animal health expertise and results-focused resources for high-performing teams and leaders.
Veterinarians, Dairy producers, Beef producers, Equine Specialists, Pork producers, Poultry producers, Managers, Business Owners and Staff
Home / Products / Cats & Dogs / VANGUARD® Rapid Resp Intranasal
Single-nostril (0.5 mL) respiratory vaccines
This family of single-nostril (0.5 mL) respiratory vaccines helps protect dogs from key pathogens associated with Canine Infectious Respiratory Disease (CIRD) and can make administration fast and comfortable.
Indications:For the vaccination of healthy dogs 8 weeks of age or older against canine adenovirus Type 2 (CAV-2) virus, canine parainfluenza (CPI) virus and Bordetella bronchiseptica (Bb).
3 antigenic combinations:
Bb + CPiV + CAV-2
Bb + CPiV
Infectious respiratory disease in dogs can be caused by many different pathogens, both bacterial and viral. In most instances, the clinical signs will be identical regardless of the infecting pathogen.
Because co-infections frequently occur and may lead to more severe symptoms, a multivalent immunization protocol can help PREVENT THE PREVENTABLE.
VANGUARD® Rapid Resp has been laboratory and field tested to demonstrate efficacy and safety.
Compared to controls:
Reduced duration of Bordetella bronchiseptica nasal shedding (p<0.0001)
Reduced cough post‑challenge
No adverse events were reported in the immediate post-vaccination period.
Abnormal health events or reactions reported in the late phase post-vaccination period. (See table on the right.)
VANGUARD® Rapid Resp Intranasal vaccines have the first approved 1-year duration of immunity claim for the Bordetella bronchiseptica, CAV-2 and CPiV fractions.
Duration of coughing reduced 65% in vaccinates as compared to controls (p<0.0001)
Strong antibody response post‑challenge (days 370 to 398)
Other respiratory clinical signs reduced
Coughing was the most commonly observed clinical sign in the control group, and all control dogs coughed during at least one observation period. In contrast, only 50% of the vaccinated dogs coughed during at least one observation period.
60% of the controls coughed in consecutive observation periods as compared to only 15% of the vaccinates.
All controls developed one or more clinical signs of disease as compared to only 65% of the vaccinates.
All dogs were seronegative to CAV-2 at vaccination. CAV-2 specific serum neutralizing antibody responses were observed in all vaccinated dogs, indicating effective immunization. They maintained titers throughout the 12-month study period. All controls remained seronegative until challenge.
The vaccine significantly (p<0.0001) reduced CAV-2 shedding:
Vaccinates shed for a mean duration of 0.3 days post‑challenge.
Controls shed for a mean duration of 4.6 days post‑challenge.
Mild-moderate nasal discharge after intranasal challenge was observed in controls and vaccinates
Controls developed additional clinical signs post-challenge, which included sneezing and retching
The vaccine induced CPiV serum neutralizing (SN) antibody responses in 100% of the vaccinated dogs, while the control dogs remained seronegative until challenge
80% of the controls shed CPiV detected in nasal swabs post-challenge as compared to only 20% of the vaccinates
The vaccine significantly (p=0.0104) reduced CPiV shedding:
Controls shed for a mean duration of 2.6 days post‑challenge.
The use of intranasal and parenteral vaccines may help provide the best Bordetella bronchiseptica protection.12
When the immune system is exposed to antigens via different routes, a more robust immune response may be achieved
Mucosal administration followed by systemic vaccination can help to avoid immune exclusion, specifically in seropositive patients13
Datz C. Bordetella infections in dogs and cats: pathogenesis, clinical signs, and diagnosis. Compend Contin Educ Pract Vet. 2003a;25(12):896-901.
Datz C. Bordetella infections in dogs and cats: pathogenesis, clinical signs, and diagnosis. Compend Contin Educ Pract Vet. 2003b;25(12):902-914.
Ford RB. Bordetella bronchiseptica: beyond kennel cough. In: Bonagura JD, Twedt DC, eds. Kirk’s Current Veterinary Therapy XIV. St. Louis, MO: WB Saunders-Elsevier; 2009:646-649.
Chalker VJ, Toomey C, Opperman S, et al. Respiratory disease in kennelled dogs: serological responses to Bordetella bronchiseptica lipopolysaccharide do not correlate with bacterial isolation or clinical respiratory symptoms. Clin Diagn Lab Immunol. 2003;10(3):352-356.
Keil DJ, Fenwick B. Role of Bordetella bronchiseptica in infectious tracheobronchitis in dogs. J Am Vet Med Assoc. 1998;212(2):200-207.
Ford RB. Canine infectious tracheobronchitis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 3rd ed. St. Louis, MO: WB Saunders-Elsevier; 2006:54-61.
Data on file, Study Report No. 3161R-60-11-477, Zoetis Inc.
Data on file, Study Report No. B961-R-US-14-147, Zoetis Inc.
Data on file, Study Report No. 3161R-60-11-498, Zoetis Inc.
Data on file, Study Report No. B864R-US-14-151, Zoetis Inc.
Data on file, Study Report No. B864R-US-15-200, Zoetis Inc.
Ellis JA, Krakowka GS, Dayton AD, Konoby C. Comparative efficacy of an injectable vaccine and an intranasal vaccine stimulating Bordetella bronchiseptica-reactive antibody responses in seropositive dogs. J Am Vet Med Assoc. 2002;220(1):43-48.
Ellis JA, Haines DM, West KH, et al. Effect of vaccination on experimental infection with Bordetella bronchiseptica in dogs. J Am Vet Med Assoc. 2001;218(3):367-375.
2011 AAHA canine vaccination guidelines. American Animal Hospital Association. https://www.aaha.org/professional/resources/canine_vaccine.aspx. Accessed November 6, 2017.
The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.©2018 Zoetis Services LLC. All rights reserved. SAB-00290R3
Mon–Fri, 8am–8pm ET
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
This site is intended for U.S. Animal Healthcare Professionals.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2017 Zoetis Services LLC. All rights reserved.